Statins in patients with kidney failure: Efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplants;Prescription des statines en cas d'insuffisance rénale: Efficacité, tolérance et maniement chez le patient insuffisant rénal et chez le patient transplanté rénal

Presse Medicale

Volumn 35, Issue 2 I, 2006, Pages 219-229

  Karie, Svetlana ^a   Launay Vacher, Vincent ^a   Deray, Gilbert ^a   Isnard Bagnis, Corinne ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CYCLOSPORIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; RACTAL; ROSUVASTATIN; SIMVASTATIN; STEROID; TAHOR;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG TOLERABILITY; DYSLIPIDEMIA; GRAFT FAILURE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PROTEINURIA; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 33344474893     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74557-2     Document Type: Article

References (72)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41:1-12.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305.
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 21-27; (9435): 685-96.
4. Fellstrom B, Jardine AG, Soveri I, Cole E, Gronhagen-Riska C, Neumayer HH et al. Assessment of Lescol in Renal Transplantation trial. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation. 2005; 79: 1160-3.
5. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis. 1993; 22: 135-42.
6. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P. Dialysis modalities and dyslipidemia. Kidney Int. 2003; 84: S110-2.
7. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis. 2001; 158: 417-23.
8. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003; 14: 2084-91.
9. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982 11; 2: 1309-11.
10. Prise en charge thérapeutique du patient dyslipidémiques. Recommandations. Agence Française de Sécurité Sanitaire des produits de Santé, mars 2005.
11. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003; 41(4 Suppl 3): I-IV, S1-91.
12. Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. J Nephrol. 1997; 10: 33-40.
13. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis. 2002. 39: 283-90.
14. Harris KP, Wheeler DC, Chong CC. Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002; 61: 1469-74.
15. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol. 2003; 16: 238-44.
16. Lins RL, Matthys KL, Billiouw JM, Dratwa M, Dupont P, Lameire NH et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol. 2004; 62: 287-94.
17. Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med. 2005; 257: 438-45.
18. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003 14; 361(9374): 2024-31.
19. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002; 61: 297-304.
20. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-48.
21. Cosio FG, Pesavento TE, Pelletier RP, Henry M, Ferguson RM, Kim S et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002; 40: 638-43.
22. Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C et al. ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant. 2004; 4: 988-95.
23. Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Cavallaro E et al. Statins and progressive renal disease. Med Res Rev. 2002; 22: 76-84.
24. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF et al. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis. 1998; 31: 190-4.
25. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000; 101: 207-13.
26. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Partial remission of nephrotic syndrome in patient on long-term simvastatin. Lancet. 1990; 335: 1045-6.
27. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002; 17: 798-802.
28. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther. 2000; 67: 427-31.
29. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002; 40: 67-73.
30. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003; 41: 565-70.
31. Verhulst A, D'Haese PC, De Broe ME. Inhibitors of HMG-CoA Reductase Reduce Receptor-mediated Endocytosis in Human Kidney Proximal Tubular Cells. J Am Soc Nephrol. 2004; 15: 2249-57.
32. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ et al. Inhibitors of 3-Hydroxy-3-Methylglutaryl-CoA Reductase Reduce Receptor-Mediated Endocytosis in Opossum Kidney Cells. J Am Soc Nephrol. 2004; 15: 2258-65.
33. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001; 59: 260-9.
34. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003; 14: 1605-13.
35. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-16.
36. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004; 57: 728-34.
37. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002; 13: 2898-908.
38. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation. 1996; 61: 1469-74.
39. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 2001; 60: 1990-7.
40. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005; 111: 3051-7.
41. Deslypere JP, Delanghe J, Vermeulen A. Proteinuria as complication of simvastatin treatment. Lancet. 1990; 336: 1453.
42. van Zyl-Smit R, Firth JC, Duffield M, Marais AD. Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant. 2004; 19: 3176-9.
43. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 2002; 62: 1743-9.
44. Launay-Vacher V, Storme T, Izzedine H, Deray G. [Pharmacokinetic changes in renal failure]. Presse Med. 2001; 30: 597-604.
45. Launay-Vacher V, Izzedine H, Deray G. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol. 2005; 101: 9-17.
46. Black AE, Hayes RN, Roth BD, Woo P, Woolf TF. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos. 1999; 27: 916-23.
47. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol. 1999; 54: 851-5.
48. Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol. 1997; 37: 816-9.
49. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003; 18: 967-76.
50. Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos. 1993; 21: 567-72.
51. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens. 1993; 6: 375S-382S.
52. Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs. 1999; 57: 583-606.
53. Lintott CJ, Scott RS, Bremer JM, Shand BI. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol. 1995; 76: 97A-101A.
54. Samuelsson O, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Alaupovic P. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis. 2002; 39: 67-75.
55. Appel-Dingemanse S, Smith T, Merz M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J Clin Pharmacol. 2002; 42: 312-18.
56. Quion JA, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet. 1994; 27: 94-103.
57. Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther. 1990; 48: 201-7.
58. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol. 1990; 30: 1128-35.
59. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990; 29: 239-43.
60. Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol. 1992; 32: 124-32.
61. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003; 04: 610-6.
62. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003; 16: 45-50.
63. Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther. 2000; 38: 245-53.
64. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 2001; 297: 861-7.
65. Dimitroulakos J, Yeger H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med. 1996; 2: 326-33.
66. Veau C, Leroy C, Banide H, Auchere D, Tardivel S, Farinotti R et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant. 2001; 16:1607-14.
67. Gehr TW, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF. The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol. 1997; 53: 117-21.
68. Launay-Vacher V, Izzedine H, Baumelou A, Deray G. FHD: an index to evaluate drug elimination by hemodialysis. Am J Nephrol. 2005; 25: 342-51.
69. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001; 87(suppl): 28B-32B.
70. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atheroscler 2001; Suppl 2: 90 P174.
71. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993; 24: 195-202.
72. Briel M, Nordmann AJ, Bucher HC. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Curr Opin Lipidol. 2005; 16: 601-5.